Sunshine Biopharma (SBFM) Assets Average (2011 - 2026)

Sunshine Biopharma (SBFM) has reported Assets Average for 14 consecutive years, with $30.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Assets Average rose 0.67% year-over-year to $30.8 million; the trailing twelve-month figure through Jun 2026 stood at $30.8 million (up 0.67% YoY), and the FY2025 full-year result was $30.3 million, up 4.72% from the prior year.
• Assets Average grew to $30.8 million in Q2 2026 per SBFM's latest filing, from $29.0 million in the prior quarter.
• Across five years, Assets Average topped out at $41.4 million in Q3 2022 and bottomed at $7.8 million in Q1 2022.
• Historically, Assets Average has averaged $29.2 million across 5 years, with a median of $29.8 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Assets Average soared 1818.4% in 2022, then slumped 32.34% in 2023.
• Over 5 years, Assets Average stood at $35.1 million in 2022, then retreated by 21.55% to $27.5 million in 2023, then rose by 10.22% to $30.3 million in 2024, then advanced by 1.57% to $30.8 million in 2025, then retreated by 0.01% to $30.8 million in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $30.8 million, $29.0 million, and $30.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.